
The speakers discuss GLP-1 drugs like Ozempic for weight loss and diabetes management. One speaker acknowledges the potential benefits for morbidly obese individuals with existing health conditions, but also mentions the potential side-effects and the possibility for compounding the GLP-1 drugs at lower doses, which may provide a good cost-benefit analysis.

"The speaker mentions being called "anti-science" on CNN for suggesting caution around drugs like Ozempic. They also discuss the cost-benefit analysis of GLP-1 drugs."




